{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:03:20Z","timestamp":1784293400806,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40272-026-00751-8","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:17:46Z","timestamp":1781183866000},"page":"331-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance"],"prefix":"10.1007","volume":"28","author":[{"given":"Giulia","family":"D\u2019Arcangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Naspi Catassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Celano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-4004","authenticated-orcid":false,"given":"Marina","family":"Aloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1067\/s0022-3476(03)00444-x","volume":"143","author":"S Kugathasan","year":"2003","unstructured":"Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143:525\u201331. https:\/\/doi.org\/10.1067\/s0022-3476(03)00444-x.","journal-title":"J Pediatr"},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MPG.0000000000002842","volume":"71","author":"CJ Burgess","year":"2020","unstructured":"Burgess CJ, Henderson P, Jones G, Lees CW, Wilson DC. Pediatric patients (less than age of 17 years) account for less than 1.5% of all prevalent inflammatory bowel disease cases. J Pediatr Gastroenterol Nutr. 2020;71:521\u20133. https:\/\/doi.org\/10.1097\/MPG.0000000000002842.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ajg.2017.228","volume":"113","author":"S Ghione","year":"2018","unstructured":"Ghione S, Sarter H, Fumery M, Armengol-Debeir L, Savoye G, Ley D, et al. Dramatic increase in incidence of ulcerative colitis and Crohn\u2019s disease (1988\u20132011): a population-based study of French adolescents. Am J Gastroenterol. 2018;113:265\u201372. https:\/\/doi.org\/10.1038\/ajg.2017.228.","journal-title":"Am J Gastroenterol"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022;162:1147-1159.e4. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.282.","journal-title":"Gastroenterology"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","journal-title":"Lancet"},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.gtc.2023.05.001","volume":"52","author":"R Khan","year":"2023","unstructured":"Khan R, Kuenzig ME, Benchimol EI. Epidemiology of pediatric inflammatory bowel disease. Gastroenterol Clin North Am. 2023;52:483\u201396. https:\/\/doi.org\/10.1016\/j.gtc.2023.05.001.","journal-title":"Gastroenterol Clin North Am"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.dld.2021.12.018","volume":"54","author":"P Alvisi","year":"2022","unstructured":"Alvisi P, Labriola F, Scarallo L, Gandullia P, Knafelz D, Bramuzzo M, et al. Epidemiological trends of pediatric IBD in Italy: a 10-year analysis of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition Registry. Dig Liver Dis. 2022;54:469\u201376. https:\/\/doi.org\/10.1016\/j.dld.2021.12.018.","journal-title":"Dig Liver Dis"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1093\/jcag\/gwad016","volume":"6","author":"W El-Matary","year":"2023","unstructured":"El-Matary W, Carroll MW, Deslandres C, Griffiths AM, Kuenzig ME, Mack DR, et al. The 2023 impact of inflammatory bowel disease in Canada: special populations\u2014children and adolescents with IBD. J Can Assoc Gastroenterol. 2023;6:S35-44. https:\/\/doi.org\/10.1093\/jcag\/gwad016.","journal-title":"J Can Assoc Gastroenterol."},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","volume":"135","author":"MD Kappelman","year":"2008","unstructured":"Kappelman MD, Rifas\u2013Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn\u2019s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907\u201313. https:\/\/doi.org\/10.1053\/j.gastro.2008.09.012.","journal-title":"Gastroenterology"},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, et al. The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation. Inflamm Bowel Dis. 2020;26:1\u201310. https:\/\/doi.org\/10.1093\/ibd\/izz104.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ibd\/izz120","volume":"26","author":"W El-Matary","year":"2020","unstructured":"El-Matary W, Kuenzig ME, Singh H, Okoli G, Moghareh M, Kumar H, et al. Disease-associated costs in children with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2020;26:206\u201315. https:\/\/doi.org\/10.1093\/ibd\/izz120.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR12","doi-asserted-by":"publisher","DOI":"10.33590\/emjgastroenterol\/10312720","author":"D Turner","year":"2019","unstructured":"Turner D. Making the invisible visible: the hidden cost of pediatric inflammatory bowel disease. EMJ Gastroenterol. 2019. https:\/\/doi.org\/10.33590\/emjgastroenterol\/10312720.","journal-title":"EMJ Gastroenterol."},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","volume":"169","author":"MJ Rosen","year":"2015","unstructured":"Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169:1053. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.1982.","journal-title":"JAMA Pediatr"},{"key":"751_CR14","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1093\/ibd\/izaf133","volume":"31","author":"M Fumery","year":"2025","unstructured":"Fumery M, Savoye G, Sarter H, Dupont-Lucas C, Bertrand V, Wils P, et al. Long-term outcome of colonic and ileal Crohn\u2019s disease: a two-decade population-based study in pediatric-onset disease. Inflamm Bowel Dis. 2025;31:3093\u2013102. https:\/\/doi.org\/10.1093\/ibd\/izaf133.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12876-016-0455-y","volume":"16","author":"M Gasparetto","year":"2016","unstructured":"Gasparetto M, Guariso G, Pozza LVD, Ross A, Heuschkel R, Zilbauer M. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterol. 2016;16:35. https:\/\/doi.org\/10.1186\/s12876-016-0455-y.","journal-title":"BMC Gastroenterol"},{"key":"751_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003557","author":"BS Akkelle","year":"2022","unstructured":"Akkelle BS, Ertem D, Volkan B, Tutar E. Phenotypic pattern of early versus later-onset pediatric inflammatory bowel disease in a Eurasian country. J Pediatr Gastroenterol Nutr. 2022. https:\/\/doi.org\/10.1097\/MPG.0000000000003557.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"751_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","volume":"15","author":"PF Van Rheenen","year":"2021","unstructured":"Van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of pediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2021;15:171\u201394. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa161.","journal-title":"J Crohns Colitis"},{"key":"751_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ibd\/izz157","volume":"26","author":"W El-Matary","year":"2019","unstructured":"El-Matary W, Leung S, Tennakoon A, Benchimol EI, Bernstein CN, Targownik LE. Trends of utilization of tumor necrosis factor antagonists in children with inflammatory bowel disease: a Canadian population-based study. Inflamm Bowel Dis. 2019;26:134\u20138. https:\/\/doi.org\/10.1093\/ibd\/izz157.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/apt.17217","volume":"56","author":"CJ Burgess","year":"2022","unstructured":"Burgess CJ, Jackson R, Chalmers I, Russell RK, Hansen R, Scott G, et al. The inexorable increase of biologic exposure in pediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study. Aliment Pharmacol Ther. 2022;56:1453\u20139. https:\/\/doi.org\/10.1111\/apt.17217.","journal-title":"Aliment Pharmacol Ther"},{"key":"751_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ecco-jcc\/jjab204","volume":"16","author":"O Atia","year":"2022","unstructured":"Atia O, Orlanski-Meyer E, Lujan R, Ledderman N, Greenfeld S, Kariv R, et al. Improved outcomes of pediatric and adult Crohn\u2019s disease and association with emerging use of biologics\u2014a nationwide study from the Epi-IIRN. J Crohns Colitis. 2022;16:778\u201385. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab204.","journal-title":"J Crohns Colitis"},{"key":"751_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/MPG.0000000000003301","volume":"74","author":"G D\u2019Arcangelo","year":"2022","unstructured":"D\u2019Arcangelo G, Abi Nader E, Charbit-Henrion F, Talbotec C, Goulet O, Ruemmele FM, et al. Increased use of anti-tumor necrosis factor following the implementation of the ECCO\u2013ESPGHAN guidelines and its impact on the outcome of pediatric Crohn\u2019s disease. J Pediatr Gastroenterol Nutr. 2022;74:79\u201384. https:\/\/doi.org\/10.1097\/MPG.0000000000003301.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.14309\/ajg.0000000000002316","volume":"118","author":"D Ley","year":"2023","unstructured":"Ley D, Leroyer A, Dupont C, Sarter H, Bertrand V, Spyckerelle C, et al. New therapeutic strategies are associated with a significant decrease in colectomy rate in pediatric ulcerative colitis. Am J Gastroenterol. 2023;118:1997\u20132004. https:\/\/doi.org\/10.14309\/ajg.0000000000002316.","journal-title":"Am J Gastroenterol"},{"key":"751_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S2468-1253(24)00355-8","volume":"10","author":"MJ Temido","year":"2025","unstructured":"Temido MJ, Honap S, Jairath V, Vermeire S, Danese S, Portela F, et al. Overcoming the challenges of overtreating and undertreating inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2025;10:462\u201374. https:\/\/doi.org\/10.1016\/S2468-1253(24)00355-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:415\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"751_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/gutjnl-2017-315199","volume":"68","author":"A Levine","year":"2019","unstructured":"Levine A, Kori M, Kierkus J, Sigall Boneh R, Sladek M, Escher JC, et al. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate pediatric Crohn\u2019s disease\u202f: a randomised controlled trial. Gut. 2019;68:239\u201347. https:\/\/doi.org\/10.1136\/gutjnl-2017-315199.","journal-title":"Gut"},{"key":"751_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/jpn3.12430","volume":"80","author":"MT Fioretti","year":"2025","unstructured":"Fioretti MT, Gianolio L, Armstrong K, Rabone RM, Henderson P, Wilson DC, et al. A decade of real-world clinical experience with 8-week azithromycin-metronidazole combined therapy in pediatric Crohn\u2019s disease. J Pediatr Gastroenterol Nutr. 2025;80:300\u20137. https:\/\/doi.org\/10.1002\/jpn3.12430.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/ibd.20867","volume":"15","author":"D Turner","year":"2009","unstructured":"Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, et al. Appraisal of the pediatric Ulcerative Colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15:1218\u201323. https:\/\/doi.org\/10.1002\/ibd.20867.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/jpn3.70097","volume":"81","author":"E Wine","year":"2025","unstructured":"Wine E, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M, et al. Management of pediatric ulcerative colitis, part 1: ambulatory care\u2014an updated evidence-based consensus guideline from the European Society of Pediatric Gastroenterology, Hepatology and Nutrition and the European Crohn\u2019s and Colitis Organisation. J Pediatr Gastroenterol Nutr. 2025;81:765\u2013815. https:\/\/doi.org\/10.1002\/jpn3.70097.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395. https:\/\/doi.org\/10.1056\/NEJMoa0904492.","journal-title":"N Engl J Med"},{"key":"751_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","volume":"17","author":"J-F Colombel","year":"2019","unstructured":"Colombel J-F, Adedokun OJ, Gasink C, Gao L-L, Cornillie FJ, D\u2019Haens GR, et al. Combination therapy with Infliximab and azathioprine improves Infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol. 2019;17:1525-1532.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.09.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"751_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/ecco-jcc\/jjab205","volume":"16","author":"O Atia","year":"2022","unstructured":"Atia O, Harel S, Ledderman N, Greenfeld S, Kariv R, Dotan I, et al. Risk of cancer in pediatric onset Inflammatory Bowel diseases: a nation-wide study from the epi-IIRN. J Crohns Colitis. 2022;16:786\u201395. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab205.","journal-title":"J Crohns Colitis"},{"key":"751_CR33","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1053\/j.gastro.2020.06.030","volume":"159","author":"VS Kj\u00e6rgaard","year":"2020","unstructured":"Kj\u00e6rgaard VS, Jensen CB, Elmahdi R, Burisch J, Allin KH, Jess T. Cancer risk in pediatric-onset Inflammatory bowel disease: a population-based Danish cohort study. Gastroenterology. 2020;159:1609\u201311. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.030.","journal-title":"Gastroenterology"},{"key":"751_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103321","volume":"149","author":"A Ehrstr\u00f6m","year":"2024","unstructured":"Ehrstr\u00f6m A, Jansson S, J\u00f8rgensen MH, Wewer V, Malham M. The risk of cancer in pediatric-onset immune-mediated inflammatory diseases \u2013 a nationwide study. J Autoimmun. 2024;149:103321. https:\/\/doi.org\/10.1016\/j.jaut.2024.103321.","journal-title":"J Autoimmun"},{"key":"751_CR35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679. https:\/\/doi.org\/10.1001\/jama.2017.16071.","journal-title":"JAMA"},{"issue":"9","key":"751_CR36","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","volume":"12","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443\u201351. https:\/\/doi.org\/10.1016\/j.cgh.2014.01.021.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"751_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72:517\u201324. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201244.","journal-title":"Ann Rheum Dis"},{"key":"751_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18277","author":"M Zamani","year":"2024","unstructured":"Zamani M, Alizadeh-Tabari S, Murad MH, Singh S, Ananthakrishnan AN, Malekzadeh R, et al. Meta-analysis: risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies. Aliment Pharmacol Ther. 2024. https:\/\/doi.org\/10.1111\/apt.18277.","journal-title":"Aliment Pharmacol Ther"},{"key":"751_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3190548","volume":"2018","author":"PC Church","year":"2018","unstructured":"Church PC, Hyams J, Ruemmele F, de Ridder L, Turner D, Griffiths AM. The continental divide: anti-TNF use in pediatric IBD is different in North America compared to other parts of the world. Can J Gastroenterol Hepatol. 2018;2018:1\u20138. https:\/\/doi.org\/10.1155\/2018\/3190548.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"751_CR40","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","volume":"179","author":"MME Jongsma","year":"2020","unstructured":"Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho K-L, et al. Infliximab in young pediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179:1935\u201344. https:\/\/doi.org\/10.1007\/s00431-020-03750-0.","journal-title":"Eur J Pediatr"},{"key":"751_CR41","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/ecco-jcc\/jjz019","volume":"13","author":"PC Church","year":"2019","unstructured":"Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, et al. Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory pediatric ulcerative colitis. J Crohns Colitis. 2019;13:982\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz019.","journal-title":"J Crohns Colitis"},{"key":"751_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00365521.2025.2597263","volume":"61","author":"\u017d \u0160ubic","year":"2026","unstructured":"\u0160ubic \u017d, Drobne D, Novak G. High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study. Scand J Gastroenterol. 2026;61:95\u2013103. https:\/\/doi.org\/10.1080\/00365521.2025.2597263.","journal-title":"Scand J Gastroenterol"},{"key":"751_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.dld.2023.08.042","volume":"56","author":"T Bessissow","year":"2024","unstructured":"Bessissow T, Narula N, Ma C, In TSH, Eberg M, Karra K, et al. Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn\u2019s disease: a Canadian multi-center study. Dig Liver Dis. 2024;56:61\u20139. https:\/\/doi.org\/10.1016\/j.dld.2023.08.042.","journal-title":"Dig Liver Dis"},{"key":"751_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/MEG.0000000000002940","volume":"37","author":"E Supovec","year":"2025","unstructured":"Supovec E, Han\u017eel J, Novak G, Manevski D, \u0160tabuc B, Drobne D. First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn\u2019 disease, but not in ulcerative colitis. Eur J Gastroenterol Hepatol. 2025;37:557\u201364. https:\/\/doi.org\/10.1097\/MEG.0000000000002940.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"751_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.1248","author":"U Shani","year":"2026","unstructured":"Shani U, Yaakobi H, Leibovitzh H, Maharshak N, Abitbol CM, Ungar B, et al. P1067 comparative effectiveness of first-line ustekinumab, vedolizumab and anti-TNF for Crohn\u2019s disease\u2014a real-world study at two tertiary centers. J Crohns Colitis. 2026. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf231.1248.","journal-title":"J Crohns Colitis"},{"key":"751_CR46","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/jpn3.70275","volume":"82","author":"D Turner","year":"2026","unstructured":"Turner D, Assa A, Malham M, Bar-Asher SY, Rayan C, Hyams JS, et al. Reshaping study design for faster extrapolation-based drug approval in pediatric inflammatory bowel diseases: an ESPGHAN\u2013NASPGHAN position paper. J Pediatr Gastroenterol Nutr. 2026;82:867\u201394. https:\/\/doi.org\/10.1002\/jpn3.70275.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/gutjnl-2018-317987","volume":"69","author":"D Turner","year":"2020","unstructured":"Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, et al. Designing clinical trials in pediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020;69:32\u201341. https:\/\/doi.org\/10.1136\/gutjnl-2018-317987.","journal-title":"Gut"},{"key":"751_CR48","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","volume":"2","author":"CY Ponsioen","year":"2017","unstructured":"Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2:785\u201392. https:\/\/doi.org\/10.1016\/S2468-1253(17)30248-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"751_CR49","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15425","volume":"50","author":"M Logan","year":"2019","unstructured":"Logan M, Clark CM, Ijaz UZ, Gervais L, Duncan H, Garrick V, et al. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re\u2010introduction. Aliment Pharmacol Ther. 2019;50:664\u201374. https:\/\/doi.org\/10.1111\/apt.15425.","journal-title":"Aliment Pharmacol Ther"},{"key":"751_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.gastro.2019.04.021","volume":"157","author":"A Levine","year":"2019","unstructured":"Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, et al. Crohn\u2019s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157:440-450.e8. https:\/\/doi.org\/10.1053\/j.gastro.2019.04.021.","journal-title":"Gastroenterology"},{"key":"751_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf122","author":"V Svolos","year":"2025","unstructured":"Svolos V, Gordon H, Lomer MCE, Aloi M, Bancil A, Day AS, et al. European Crohn\u2019s and Colitis Organisation consensus on dietary management of inflammatory bowel disease. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf122.","journal-title":"J Crohns Colitis"},{"key":"751_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae177","volume":"19","author":"A Jatkowska","year":"2025","unstructured":"Jatkowska A, White B, Gkikas K, Seenan JP, MacDonald J, Gerasimidis K. Partial enteral nutrition in the management of Crohn\u2019s Disease: a systematic review and meta-analysis. J Crohns Colitis. 2025;19:jjae177. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae177.","journal-title":"J Crohns Colitis"},{"key":"751_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-020-00773-3","author":"MA Conrad","year":"2020","unstructured":"Conrad MA, Kelsen JR. The treatment of pediatric inflammatory bowel disease with biologic therapies. Curr Gastroenterol Rep. 2020. https:\/\/doi.org\/10.1007\/s11894-020-00773-3.","journal-title":"Curr Gastroenterol Rep"},{"key":"751_CR54","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","volume":"157","author":"A Assa","year":"2019","unstructured":"Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring. Gastroenterology. 2019;157:985-996.e2. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.003.","journal-title":"Gastroenterology"},{"key":"751_CR55","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","volume":"69","author":"K Clarkston","year":"2019","unstructured":"Clarkston K, Tsai Y, Jackson K, Rosen MJ, Denson LA, Minar P. Development of infliximab target concentrations during induction in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2019;69:68\u201374. https:\/\/doi.org\/10.1097\/MPG.0000000000002304.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR56","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/apt.17936","volume":"59","author":"A Ricciuto","year":"2024","unstructured":"Ricciuto A, Liu K, El-Matary W, Amin M, Amir AZ, Aumar M, et al. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Pediatric PSC Consortium. Aliment Pharmacol Ther. 2024;59:1236\u201347. https:\/\/doi.org\/10.1111\/apt.17936.","journal-title":"Aliment Pharmacol Ther"},{"key":"751_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.70180","author":"S Ancona","year":"2025","unstructured":"Ancona S, Gianolio L, Armstrong K, Rabone R, Merrick V, Henderson P, et al. Effectiveness and safety of oral vancomycin in non-primary sclerosing cholangitis pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2025. https:\/\/doi.org\/10.1002\/jpn3.70180.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001605","author":"L R\u00e4is\u00e4nen","year":"2025","unstructured":"R\u00e4is\u00e4nen L, Balouch F, McLaren-Kennedy A, Clark JE, Lewindon P. Outcomes of oral vancomycin therapy in children with atypical ulcerative colitis with or without confirmed primary sclerosing cholangitis: a real-world observational study. BMJ Open Gastroenterol. 2025. https:\/\/doi.org\/10.1136\/bmjgast-2024-001605.","journal-title":"BMJ Open Gastroenterol"},{"key":"751_CR59","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/ibd\/izad120","volume":"30","author":"S Bhat","year":"2024","unstructured":"Bhat S, Click B, Regueiro M. Safety and monitoring of inflammatory bowel disease advanced therapies. Inflamm Bowel Dis. 2024;30:829\u201343. https:\/\/doi.org\/10.1093\/ibd\/izad120.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30. https:\/\/doi.org\/10.1186\/1710-1492-9-30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"751_CR61","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847-858.e4. https:\/\/doi.org\/10.1016\/j.cgh.2014.05.015.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"751_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MPG.0000000000003781","volume":"77","author":"M Malham","year":"2023","unstructured":"Malham M, Jansson S, Malmborg P, Ol\u00e9n O, Paerregaard A, Virta LJ, et al. Risk factors of cancer in pediatric-onset Inflammatory Bowel Disease in Denmark and Finland. J Pediatr Gastroenterol Nutr. 2023;77:55\u201361. https:\/\/doi.org\/10.1097\/MPG.0000000000003781.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae182","volume":"19","author":"A Yerushalmy-Feler","year":"2025","unstructured":"Yerushalmy-Feler A, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, et al. Upadacitinib for induction of remission in pediatric ulcerative colitis: an international multicenter study. J Crohns Colitis. 2025;19:jjae182. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae182.","journal-title":"J Crohns Colitis"},{"key":"751_CR64","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/apt.70016","volume":"61","author":"S Cohen","year":"2025","unstructured":"Cohen S, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, et al. Upadacitinib for induction of remission in pediatric Crohn\u2019s Disease: an international multicentre retrospective study. Aliment Pharmacol Ther. 2025;61:1372\u201380. https:\/\/doi.org\/10.1111\/apt.70016.","journal-title":"Aliment Pharmacol Ther"},{"key":"751_CR65","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1093\/ibd\/izaf166","volume":"31","author":"A Yerushalmy-Feler","year":"2025","unstructured":"Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, et al. Real-world experience with Upadacitinib for pediatric acute severe Ulcerative Colitis: an international multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN. Inflamm Bowel Dis. 2025;31:3320\u20136. https:\/\/doi.org\/10.1093\/ibd\/izaf166.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR66","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1053\/j.gastro.2018.12.002","volume":"156","author":"V Svolos","year":"2019","unstructured":"Svolos V, Hansen R, Nichols B, Quince C, Ijaz UZ, Papadopoulou RT, et al. Treatment of active Crohn\u2019s Disease with an ordinary food-based diet that replicates Exclusive Enteral Nutrition. Gastroenterology. 2019;156:1354-1367.e6. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.002.","journal-title":"Gastroenterology"},{"key":"751_CR67","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1053\/j.gastro.2025.06.011","volume":"169","author":"Y Aharoni-Frutkoff","year":"2025","unstructured":"Aharoni-Frutkoff Y, Plotkin L, Pollak D, Livovsky J, Focht G, Lev-Tzion R, et al. Whole food diet induces remission in children and young adults with mild to moderate Crohn\u2019s disease and is more tolerable than Exclusive Enteral Nutrition: a randomized controlled trial. Gastroenterology. 2025;169:1462-1474.e2. https:\/\/doi.org\/10.1053\/j.gastro.2025.06.011.","journal-title":"Gastroenterology"},{"key":"751_CR68","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1093\/ibd\/izad255","volume":"30","author":"R Sigall Boneh","year":"2024","unstructured":"Sigall Boneh R, Westoby C, Oseran I, Sarbagili-Shabat C, Albenberg LG, Lionetti P, et al. The Crohn\u2019s disease exclusion diet: a comprehensive review of evidence, implementation strategies, practical guidance, and future directions. Inflamm Bowel Dis. 2024;30:1888\u2013902. https:\/\/doi.org\/10.1093\/ibd\/izad255.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR69","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.cgh.2024.12.006","volume":"23","author":"R Sigall Boneh","year":"2025","unstructured":"Sigall Boneh R, Navas-L\u00f3pez VM, Hussey S, Pujol-Muncunill G, Lawrence S, Rolandsdotter H, et al. Modified Crohn\u2019s disease exclusion diet maintains remission in pediatric Crohn\u2019s disease: randomized controlled trial. Clin Gastroenterol Hepatol. 2025;23:2001\u201311. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.006.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"751_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ecco-jcc\/jjac105","volume":"17","author":"CM Verburgt","year":"2023","unstructured":"Verburgt CM, Dunn KA, Ghiboub M, Lewis JD, Wine E, Sigall Boneh R, et al. Successful dietary therapy in pediatric Crohn\u2019s disease is associated with shifts in bacterial dysbiosis and inflammatory metabotype towards healthy controls. J Crohns Colitis. 2023;17:61\u201372. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac105.","journal-title":"J Crohns Colitis"},{"key":"751_CR71","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S2468-1253(25)00262-6","volume":"11","author":"B Pigneur","year":"2026","unstructured":"Pigneur B, Martinez-Vinson C, Bourmaud A, Dabadie A, Duclaux-Loras R, Hugot J-P, et al. Cyclic Exclusive Enteral Nutrition versus Partial Enteral Nutrition to maintain long-term drug-free remission in pediatric Crohn\u2019s Disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial. Lancet Gastroenterol Hepatol. 2026;11:204\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(25)00262-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"751_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","volume":"12","author":"G Doherty","year":"2018","unstructured":"Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, et al. European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease. J Crohns Colitis. 2018;12:17\u201331. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx101.","journal-title":"J Crohns Colitis"},{"key":"751_CR73","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/jpn3.70036","volume":"80","author":"Y Elimeleh","year":"2025","unstructured":"Elimeleh Y, Feler AY, Badarni RT, Lahad A, Rinawi F. Safety and efficacy of adalimumab 40 mg every 3 weeks in pediatric-onset Crohn\u2019s disease. J Pediatr Gastroenterol Nutr. 2025;80:998\u20131001. https:\/\/doi.org\/10.1002\/jpn3.70036.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.708310","author":"J Meredith","year":"2021","unstructured":"Meredith J, Henderson P, Wilson DC, Russell RK. Combination immunotherapy use and withdrawal in pediatric inflammatory bowel disease\u2014a review of the evidence. Front Pediatr. 2021. https:\/\/doi.org\/10.3389\/fped.2021.708310.","journal-title":"Front Pediatr"},{"key":"751_CR75","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/jpn3.12299","volume":"79","author":"NA Iovino","year":"2024","unstructured":"Iovino NA, McClinchie MG, Abdel-Rasoul M, Boyle B, Dotson JL, Michel HK, et al. Clinical impacts of immunomodulator withdrawal from anti-tumor necrosis factor combination therapy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024;79:885\u201394. https:\/\/doi.org\/10.1002\/jpn3.12299.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR76","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/jpn3.70297","volume":"82","author":"S Cekin","year":"2026","unstructured":"Cekin S, Huenseler C, Cantez S, Broekaert I, de Laffolie J. Therapy de-escalation in pediatric patients with inflammatory bowel disease in remission: data analysis from the CEDATA registry. J Pediatr Gastroenterol Nutr. 2026;82:690\u20138. https:\/\/doi.org\/10.1002\/jpn3.70297.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR77","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/MPG.0000000000002857","volume":"71","author":"W El-Matary","year":"2020","unstructured":"El-Matary W, Carroll MW, Debruyn JC, Huynh H, Wine E, Lawrence S, et al. Discontinuation of immunosuppressive medications in children with inflammatory bowel disease on combination therapy. J Pediatr Gastroenterol Nutr. 2020;71:740\u20133. https:\/\/doi.org\/10.1097\/MPG.0000000000002857.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR78","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrgastro.2009.124","volume":"6","author":"TD Walters","year":"2009","unstructured":"Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn\u2019s disease. Nat Rev Gastroenterol Hepatol. 2009;6:513\u201323. https:\/\/doi.org\/10.1038\/nrgastro.2009.124.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"751_CR79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/MPG.0000000000002865","volume":"72","author":"A Gourdonneau","year":"2021","unstructured":"Gourdonneau A, Bruneau L, Ruemmele FM, Norsa L, Takeda A, Le Gall C, et al. Clinical remission and psychological management are major issues for the quality of life in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2021;72:74\u20139. https:\/\/doi.org\/10.1097\/MPG.0000000000002865.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR80","doi-asserted-by":"publisher","DOI":"10.1097\/pg9.0000000000000215","author":"CA Lepus","year":"2022","unstructured":"Lepus CA, Hyams JS. Barriers from third\u2010party payers to biologic use in pediatric inflammatory bowel disease. JPGN Rep. 2022. https:\/\/doi.org\/10.1097\/pg9.0000000000000215.","journal-title":"JPGN Rep"},{"key":"751_CR81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jpr3.70004","volume":"6","author":"BD Constant","year":"2025","unstructured":"Constant BD, Adler J, Gold BD, Dotson J, Lightdale JR, Scott F, et al. National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease. JPGN Rep. 2025;6:80\u201390. https:\/\/doi.org\/10.1002\/jpr3.70004.","journal-title":"JPGN Rep"},{"key":"751_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf125","author":"A El-Hussuna","year":"2026","unstructured":"El-Hussuna A, Hauer AC, Karakan T, Pittet V, Yanai H, Devi J, et al. ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries. J Crohns Colitis. 2026. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf125.","journal-title":"J Crohns Colitis"},{"key":"751_CR83","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jpn3.70121","volume":"81","author":"AC Hauer","year":"2025","unstructured":"Hauer AC, Sultan M, Darma A, Altamimi E, Serban DE, Assa A, et al. Management of pediatric inflammatory bowel diseases in limited\u2010resource settings: a position paper from the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2025;81:866\u201398. https:\/\/doi.org\/10.1002\/jpn3.70121.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR84","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","volume":"19","author":"L Tsai","year":"2021","unstructured":"Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19:2031-2045.e11. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.039.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"751_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf239","volume":"20","author":"G Privitera","year":"2026","unstructured":"Privitera G, Bezzio C, Buono AD, Gabbiadini R, Loy L, Ranucci L, et al. Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis\u2014the TACTIC-UC study. J Crohns Colitis. 2026;20(2):jjaf239. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf239.","journal-title":"J Crohns Colitis"},{"key":"751_CR86","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/ibd\/izae298","volume":"31","author":"G Scott","year":"2025","unstructured":"Scott G, Wands DIF, Wilson DC, Hansen R, Chalmers I. Selecting high-risk patients with pediatric Crohn\u2019s disease for top-down Anti-TNF as per the 2021 ECCO-ESPGHAN guidelines: a 5-year nationwide retrospective analysis from Scotland (2016-2020). Inflamm Bowel Dis. 2025;31:2059\u201365. https:\/\/doi.org\/10.1093\/ibd\/izae298.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR87","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/ecco-jcc\/jjab210","volume":"16","author":"O Atia","year":"2022","unstructured":"Atia O, Orlanski-Meyer E, Lujan R, Ledderman N, Greenfeld S, Kariv R, et al. Colectomy rates did not decrease in pediatric- and adult-onset ulcerative colitis during the biologics era: a nationwide study from the epi-IIRN. J Crohns Colitis. 2022;16:796\u2013803. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab210.","journal-title":"J Crohns Colitis"},{"key":"751_CR88","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","volume":"22","author":"R Atreya","year":"2024","unstructured":"Atreya R, Neurath MF. Biomarkers for personalizing IBD therapy: the quest continues. Clin Gastroenterol Hepatol. 2024;22:1353\u201364. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.026.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"751_CR89","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/ibd\/izae084","volume":"30","author":"S Syed","year":"2024","unstructured":"Syed S, Boland BS, Bourke LT, Chen LA, Churchill L, Dobes A, et al. Challenges in IBD research 2024: precision medicine. Inflamm Bowel Dis. 2024;30:S39-54. https:\/\/doi.org\/10.1093\/ibd\/izae084.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR90","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2517828","author":"E Vermeer","year":"2025","unstructured":"Vermeer E, Jagt JZ, Lap EM, Struys EA, Budding AE, Verhoeven-Duif NM, et al. Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of pediatric inflammatory bowel disease. Gut Microbes. 2025. https:\/\/doi.org\/10.1080\/19490976.2025.2517828.","journal-title":"Gut Microbes"},{"key":"751_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.70357","author":"CM Verburgt","year":"2026","unstructured":"Verburgt CM, van der Kruk N, Dunn KA, Van Limbergen JE. Personalized AZithromycin\/metronidAZole\u2009+\u2009dietary therapy in pediatric Crohn disease: results of a pilot study. J Pediatr Gastroenterol Nutr. 2026. https:\/\/doi.org\/10.1002\/jpn3.70357.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"751_CR92","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1093\/ibd\/izad275","volume":"30","author":"M Distante","year":"2024","unstructured":"Distante M, Rotulo S, Ranalli M, Pedace E, Lionetti P, Arrigo S, et al. Clusters of disease activity and early risk factors of clinical course of pediatric Crohn\u2019s disease. Inflamm Bowel Dis. 2024;30:1983\u201391. https:\/\/doi.org\/10.1093\/ibd\/izad275.","journal-title":"Inflamm Bowel Dis"},{"key":"751_CR93","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ecco-jcc\/jjaa203","volume":"15","author":"M Aloi","year":"2021","unstructured":"Aloi M, Bramuzzo M, Norsa L, Arrigo S, Distante M, Miele E, et al. Disease activity patterns in the first 5 years after diagnosis in children with ulcerative colitis: a population-based study. J Crohns Colitis. 2021;15:367\u201374. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa203.","journal-title":"J Crohns Colitis"},{"key":"751_CR94","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ueg2.12720","volume":"13","author":"L Chen","year":"2025","unstructured":"Chen L, Zhang C, Niu R, Xiong S, He J, Wang Y, et al. Multi\u2010omics biomarkers for predicting efficacy of biologic and small\u2010molecule therapies in adults with inflammatory bowel disease: a systematic review. United Eur Gastroenterol J. 2025;13:517\u201330. https:\/\/doi.org\/10.1002\/ueg2.12720.","journal-title":"United Eur Gastroenterol J"},{"key":"751_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae197","author":"AJ Preto","year":"2025","unstructured":"Preto AJ, Chanana S, Ence D, Healy MD, Domingo-Fern\u00e1ndez D, West KA. Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae197.","journal-title":"J Crohns Colitis"},{"key":"751_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07024-x","volume":"23","author":"Y Tao","year":"2025","unstructured":"Tao Y, Wang L-F, Li P, Sun R, Li Y-J, Sun M, et al. Decoding IBD progression: a dynamic biomarker atlas for personalized disease stratification. J Transl Med. 2025;23:1076. https:\/\/doi.org\/10.1186\/s12967-025-07024-x.","journal-title":"J Transl Med"},{"key":"751_CR97","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf172","author":"O Rotem-Tryfus","year":"2025","unstructured":"Rotem-Tryfus O, Kang B, Orlanski-Meyer E, Ledder O, Lev Tzion R, Choi S, et al. Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn\u2019s disease: a systematic review and prospective cohort study. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf172.","journal-title":"J Crohns Colitis"},{"key":"751_CR98","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/jpn3.70096","volume":"81","author":"A Assa","year":"2025","unstructured":"Assa A, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M, et al. Management of pediatric ulcerative colitis, part 2: acute severe colitis\u2014an updated evidence-based consensus guideline from the European Society of Pediatric Gastroenterology, Hepatology and Nutrition and the European Crohn\u2019s and Colitis Organization. J Pediatr Gastroenterol Nutr. 2025;81:816\u201351. https:\/\/doi.org\/10.1002\/jpn3.70096.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00751-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00751-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00751-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:11:04Z","timestamp":1784290264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00751-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00751-8","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No honorarium, grant, or other form of payment was given to anyone to write and produce the manuscript.","order":2,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marina Aloi is an Editorial Board member of Pediatric Drugs. Dr Aloi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.All other authors have no financial disclosures or conflicts of interest related to the article to declare.","order":3,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":5,"name":"Ethics","label":"Consent to participate\/Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":6,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giulia D\u2019Arcangelo, as first author, contributed substantially to the conception and development of the manuscript. She performed the literature search and review, analyzed and interpreted the relevant literature, drafted the manuscript, and critically revised its content throughout the writing process.  Silvana Ancona contributed to the literature search and review, conducted the figure production, and contributed to the writing of the manuscript.  Giulia Naspi Catassi contributed to the literature search, figure editing, revision of the manuscript draft, and approval of the final version for publication.  Francesca Musto contributed to the literature search, figure editing, revision of the manuscript draft, and approval of the final version for publication.  Rosaria Celano contributed to the literature search, figure editing, revision of the manuscript draft, and approval of the final version for publication.  Marina Aloi, as corresponding author, contributed to the conception of the manuscript, supervised the overall process, critically reviewed the content, edited and revised the final version, and approved the final version for publication.","order":8,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}